

Kluwer Patent Blog

Mundipharma v. Sandoz, District Court The Hague (Rechtbank Den Haag), 7 April 2010

Peter Burgers (Brinkhof) · Friday, April 30th, 2010

The District Court of The Hague granted Mundipharma a provisional injunction against Sandoz for infringement of its patent for a controlled release oxycodon formulation. The District Court suspended its decision on the validity and infringement of the patent in the main action until a final decision has been rendered in the opposition proceedings.

The Court extensively deals with Sandoz' numerous invalidity arguments. Of special interest are the Court's considerations on the use of disclaimers, specifically in light of the Enlarged Board of Appeal's decision G1/03.

A [full summary](#) of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how [Kluwer IP Law](#) can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change



This entry was posted on Friday, April 30th, 2010 at 9:38 am and is filed under [Case Law](#), [Chemical Engineering](#), [Disclaimer](#), [Inventive step](#), [Netherlands](#), [Novelty](#), [Opposition](#), [Revocation](#), [Validity](#). You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.